

19 September 2025

**ONDINE BIOMEDICAL INC.**

("Ondine Biomedical", "Ondine" or the "Company")

**Notice of Interim Results and Investor Presentation**

Ondine Biomedical Inc. (AIM: OBI) announces that it will publish its unaudited interim financial results for the period ended 30 June 2025 ("Half Year Results") on 26 September 2025.

Dr. Nicolas Loebel, President and Chief Technology Officer, and Alan Thomas, Interim Chief Financial Officer, of the Company, will provide a live presentation relating to the Half Year Results via Investor Meet Company on 26 September 2025 at 16:30 BST (08:30 Pacific time).

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 25 September 2025, 09:00 BST (01:00 Pacific time), or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet ONDINE BIOMEDICAL INC. via:

<https://www.investormeetcompany.com/ondine-biomedical-inc/register-investor>

Investors who already follow ONDINE BIOMEDICAL INC. on the Investor Meet Company platform will automatically be invited.

**Enquiries:**

**Ondine Biomedical Inc.**

Carolyn Cross, CEO

[www.ondinebio.com](http://www.ondinebio.com)

+1 604 669 0555

or via Vane Percy & Roberts

**Strand Hanson Limited (Nominated & Joint Financial Adviser)**

James Harris, Richard Johnson

+44 (0)20 7409 3494

**Peel Hunt LLP (Broker & Joint Financial Advisor)**

James Steel, Dr. Chris Golden

+44 (0)20 7418 8900

**Vane Percy & Roberts (Media Contact)**

Simon Vane Percy

+44 (0)77 1000 5910

**About Ondine Biomedical Inc.**

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved for nasal decolonisation in Canada, Australia, Mexico and several other countries under the name Steriwave<sup>®</sup>. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORBLGDCBSBDGUI